China Grants Priority Review to Akeso’s Ivonescimab for Biliary Tract Cancer
China granted priority review to Akeso’s ivonescimab for first-line biliary tract cancer.
China granted priority review to Akeso’s ivonescimab for first-line biliary tract cancer.